This page shows the latest DBV Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... The setback means that DBV’s drug loses further ground
California biotech Aimmune has been in a race to market with rival companies like France’s DBV Technologies, which filed for approval of its Viaskin Peanut skin patch-based product at ... DBV’s share price in the last few weeks.
DBV says its new filing “incorporates additional data needs on manufacturing procedures and quality controls” requested by the agency. ... GlobalData has predicted that Aimmune’s drug will have two-thirds of the market in 2027, with DBV’s drug
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...